SMS Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company.
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals reported strong FY2025-26 results with standalone net profit up 28.1% to Rs 8,760.93 lakhs on revenue of Rs 88,687.10 lakhs (vs Rs 78,274.81 lakhs last year). EPS improved to Rs 9.58 from Rs 8.07. The board approved the audited financial results with unmodified audit opinion from Suryanarayana & Suresh, Chartered Accountants. It recommended a dividend of Rs 0.40 per share (40%) and approved shifting the registered office within Hyderabad. The headline mentions change in auditors, but the actual document shows only routine appointments: M/s Annapragada & Co. as Cost Auditor and M/s Adusumilli & Associates as Internal Auditor for FY2026-27. No change in statutory auditors occurred.
Positive signals from strong profit growth and consistent auditor opinion. The misleading headline about auditor change should be disregarded as no statutory auditor change is evident in the filing.